Setting new standards in information exchange for the pharmaceutical and biotech industry
IO360° Lead Advisor and Co-Chair, Dr Axel Hoos featured in Life Science Leader on GSK’s Oncology R&D Pipeline
September 20, 2016
We are delighted to highlight the latest piece “Is Oncology Back at GSK? Did it Ever Leave?” printed in Life Science Leader featuring IO360° Lead Advisor/Co-Chair and GSK’s SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno-Oncology, Dr Axel Hoos, who delves into GSK’s diversified oncology R&D pipeline with a focus on immuno-oncology.
Dr Hoos will be co-chairing the Immuno-Oncology 360° (IO360°) program taking place February 1-3, 2017 in NYC. He will also be delivering a presentation on “Business Models for Complex Science” along with participating in two panels “Trend and Collaborations in the IO Space” and “Importance of KOLs in IO: Issues and Controversies.”
To read the full article: [Download Here]
For more information on IO360° visit: http://theconferencefor